Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial
Nutrition and Diabetes2016Vol. 6(8), pp. e228–e228
Citations Over TimeTop 10% of 2016 papers
Marloes P. van der Aa, Marieke A. J. Elst, E.M.W. van de Garde, Edgar van Mil, Catherijne A. J. Knibbe, Marja M. J. van der Vorst
Abstract
Long-term treatment with metformin in adolescents with obesity and insulin resistance results in stabilization of BMI and improved body composition compared with placebo. Therefore, metformin may be useful as an additional therapy in combination with lifestyle intervention in adolescents with obesity and insulin resistance.
Related Papers
- → Tolerability of prolonged-release metformin (Glucophage® SR) in individuals intolerant to standard metformin — results from four UK centres(2007)34 cited
- → Homeostatic model assessment of adiponectin (HOMA-Adiponectin) as a surrogate measure of insulin resistance in adolescents: Comparison with the hyperglycaemic clamp and homeostatic model assessment of insulin resistance(2019)23 cited
- → Insulin Resistance in Young Obese Subjects and Its Relation to Smoking (A Pilot Study)(2016)15 cited
- The relation between insulin resistance determined by homeostatic [corrected from haemostatic] modelling and slow coronary flow.(2008)
- → Insulin Resistance Assessment in Obese and Non-Obese Children Using Homa(2011)1 cited